Text Size

Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: Results from the VISIONARY Study Population in Spain.

Garcia-Medina, J. J.; Benitez-Del-Castillo, J.; Rodríguez-Agirretxe, I.; Lopez-Lopez, F.; Moreno-Valladares, A.


  • 2022
  • Journal of Ocular Pharmacology and Therapeutics
View publication
  • Therapeutic Area

    Glaucoma

  • Categories

    Clinical development

  • Affiliations

    Department of Ophthalmology, Hospital General Universitario Morales Meseguer, Murcia, Spain; Department of Ophthalmology, Hospital Universitario de Jerez, Jerez de la Frontera Cadiz, Spain; Department of Ophthalmology, Hospital Universitario Donostia, San Sebastian Guipuzcoa, Spain; Instituto Oftalmológico Gomez-Ulla, Santiago de Compostela Galicia, Spain; Department of Ophthalmology, Complejo Hospitalario Universitario de Albacete, Albacete, Spain

Related Publications

Omidenepag Isopropyl 0.002% versus Latanoprost 0.005% in Open-Angle Glaucoma/Ocular Hypertension: The Randomized Phase III PEONY Trial

Wang T.H.; Aung T.; Lu D.-W.; George R.; Senthil S.; Lu F.; Odani-Kawabata N.; Park K.H.


Efficacy and Safety of a Preservative-Free Latanoprost Cationic Emulsion in Patients with Open-Angle Glaucoma and Concurrent Ocular Surface Disease: A Randomized Phase 2 Study.

Bacharach, Jason; McLaurin, Eugene B.; Silverstein, Steven; Amrane, Mourad; Garrigue, Jean-Sebastien; Ismail, Dahlia; Flynn, William J.; Catiolanze Phase 2 study group


Assessment of Brain-Derived Neurotrophic Factor on Retinal Structure and Visual Function in Rodent Models of Optic Nerve Crush

Taniguchi T.; Sharif N.A.; Ota T.; Farjo R.A.; Rausch R.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022